Evotec is a leading drug discovery and development company providing high quality integrated research services to its customers in the pharmaceutical and biotechnology industries. With its strategic research alliances, Evotec AG supports its partners in various indication fields with innovative solutions from target to identification of clinical development candidates.
At our site in Martinsried/Munich, Germany, we have a unique technology platform that enables us to establish the side effect profile of drugs and to comprehensively study their influence on cellular signalling pathways. We make this technology available to pharmaceutical and biotechnology companies in the development and optimization of new active ingredients.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Employees: 501-1000
News about Evotec
26-Jan-2023 | Cooperation
Evotec announces agreement with Janssen to develop immune-based therapies
Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen ...
04-Nov-2022 | Business
Evotec completes acquisition of Central Glass Germany
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in ...
20-Sep-2022 | Manufacturing
Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse
Evotec SE officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse ...
26-Aug-2022 | Business
Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass ...
07-Jul-2022 | Cooperation
Three partners committed to combat AMR
Evotec SE, Boehringer Ingelheim and bioMérieux announced that they have formed a joint venture to create the next generation of antimicrobials along with ...
05-Jul-2022 | Business
Evotec completes acquisition of Rigenerand
Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell ...
14-Jun-2022 | Cooperation
Evotec enters a drug discovery collaboration with Janssen
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies ...